New aspects of neuroblastoma treatment: ASPHO 2011 symposium review

Pediatric Blood and Cancer

Volumn 58, Issue 7, 2012, Pages 1099-1105

  Zage, Peter E ^a   Louis, Chrystal U ^a,b   Cohn, Susan L ^c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Immunotherapy; INRG; Neuroblastoma

Indexed keywords

3F8 ANTIBODY; ALISERTIB; ANAPLASTIC LYMPHOMA KINASE; AURORA A KINASE; CH14.18 GANGLIOSIDE GD2 MONOCLONAL ANTIBODY; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; DOWN REGULATION; DRUG EFFICACY; EVENT FREE SURVIVAL; FERRITIN BLOOD LEVEL; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; LACTATE DEHYDROGENASE BLOOD LEVEL; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; NONHUMAN; OVERALL SURVIVAL; PAIN; PATHOGENESIS; PRIORITY JOURNAL; TUMOR LOCALIZATION; CHILD; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; REVIEW;

CHILD; HUMANS; IMMUNOTHERAPY; NEUROBLASTOMA;

EID: 84861665655     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24116     Document Type: Article

References (83)

1. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
2. Donfrancesco A, Jenkner A, Castellano A, et al. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Pediatr Suppl 2004;445:6-11.
3. London WB, Castel V, Monclair T, et al. Clinical and biological features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group Project. J Clin Oncol 2011;29:3286-3292.
4. Brodeur GM, Seeger RC, Barrett A, et al. International Criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988;6:1874-1881.
5. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment. J Clin Oncol 1993;11:1466-1477.
6. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) Classification System: An INRG task force report. J Clin Oncol 2009;27:289-297.
7. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) Staging System: An INRG task force report. J Clin Oncol 2009;27:298-303.
8. Schleiermacher G, Michon J, Huon I, et al. Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 2007;97:238-246.
9. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-1033.
10. Oberthuer A, Hero B, Berthold F, et al. Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 2010;28:3506-3515.
11. Vermeulen J, De Preter K, Naranjo A, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: A retrospective SIOPEN/COG/GPOH study. Lancet Oncol 2009;10:663-671.
12. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-6062.
13. Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst 2006;98:1193-1203.
14. Ohira M, Oba S, Nakamura Y, et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005;7:337-350.
15. Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res 2004;64:6883-6891.
16. Schramm A, Schulte JH, Klein-Hitpass L, et al. Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. Oncogene 2005;24:7902-7912.
17. Oberthuer A, Berthold F, Warnat P, et al. Customized oligonucleotide microarray gene expressionbased classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 2006;24:5070-5078.
18. Schramm A, Vandesompele J, Schulte JH, et al. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res 2007;13:1459-1465.
19. Kamei N, Hiyama K, Yamaoka H, et al. Evaluation of genes identified by microarray analysis in favorable neuroblastoma. Pediatr Surg Int 2009;25:931-937.
20. De Preter K, Vermeulen J, Brors B, et al. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin Cancer Res 2010;16:1532-1541.
21. Bray I, Bryan K, Prenter S, et al. Widespread dysregulation of miRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: Association of miRNA expression with survival. PLoS ONE 2009;4:e7850.
22. Wei JS, Johansson P, Chen QR, et al. MicroRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009;15:5560-5568.
23. Abe M, Watanabe N, McDonell N, et al. Identification of genes targeted by CpG island methylator phenotype in neuroblastomas, and their possible integrative involvement in poor prognosis. Oncology 2008;74:50-60.
24. Yang Q, Kiernan CM, Tian Y, et al. Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome. Clin Cancer Res 2007;13:3191-3197.
25. Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16:3-15.
26. Johnson E, Dean SM, Sondel PM. Antibody-based immunotherapy in high-risk neuroblastoma. Expert Rev Mol Med 2007;9:1-21.
27. Cheung NK, Sondel PM. Neuroblastoma immunology and immunotherapy. In: Cohn S, Cheung NK, editors. Neuroblastoma. Berlin, Heidelberg, New York: Springer Press; 2005. pp. 223-242.
28. Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: A Phase I Study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5: 1430-1440.
29. Cheung NK, Kushner BH, Yeh SD, et al. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study. Int J Oncol 1998;12:1299-1306.
30. Modak S, Cheung NK. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010;36:307-317.
31. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-265.
32. Louis CU, Brenner MK. Cellular immunotherapy for neuroblastoma: A Review of current vaccine and adoptive T Cell therapeutics. Curr Pharm Des 2009;15:424-429.
33. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324-1334.
34. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-129.
35. Yang RK, Sondel PM. Anti-GD2 strategy in the treatment of neuroblastoma. Drugs Future 2010; 35:665.
36. Kramer K, Kushner BH, Modak S, et al. Compartmental intrathecal radioimmunotherapy: Results for treatment for metastatic CNS neuroblastoma. J Neurooncol 2010;97:409-418.
37. Caruso DA, Orme LM, Amor GM, et al. Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer 2005;103: 1280-1291.
38. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific t cells and mediate tumor regression. Cancer Res 2001;61:8513-8519.
39. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood 1998;92:1941-1949.
40. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1998;9:1303-1311.
41. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood 2003;101:1718-1726.
42. Rousseau RF, Brenner MK. Vaccine therapies for pediatric malignancies. Cancer J 2005;11:331-339.
43. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-733.
44. Di Stasi A, Tey S-K, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365:1673-1683.
45. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007;15:825-833.
46. Pule MA, Savoldo B, Myers GD, et al. Virus-Specific t cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008;14: 1264-1270.
47. Louis CU, Savoldo B, Dotti G, et al. Anti-tumor activity and long-term fate of chimeric antigen receptor positive T-cells in patients with neuroblastoma. Blood 2011;118:6050-6056.
48. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930-935.
49. Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967-970.
50. Chen Y, Takita J, Choi YL, et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008;455:971-974.
51. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 2008;455:975-978.
52. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-1284.
53. Lin E, Li L, Guan Y, et al. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 2009;7:1466-1476.
54. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-449.
55. Caren H, Abel F, Kogner P, et al. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumors. Biochem J 2008;416:153-159.
56. Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res 2009;69:7338-7346.
57. Mosse YP, Wood A, Maris JM. Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 2009;15:5609-5614.
58. Zhou H, Kuang J, Zhong L, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy, and transformation. Nat Genet 1998;20:189-193.
59. Sen S, Katayama H, Sasai K. Functional significance of aurora kinase A in centrosome amplification and genomic instability. Adv Exp Med Biol 2008;617:99-108.
60. Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: A new target for anticancer drug. Recent Pat Anticancer Drug Discov 2008;3:114-122.
61. Fu S, Hu W, Kavanagh JJ, et al. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets 2006;10:77-85.
62. Hu W, Kavanagh JJ, Deaver M, et al. Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 2005;15:49-57.
63. Shang X, Burlingame SM, Okcu MF, et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009;8:2461-2469.
64. Otto T, Horn S, Brockmann M, et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009;15:67-78.
65. Maris JM, Morton CL, Gorlick R, et al. Initial testing of the Aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 2010;55:26-34.
66. Oppenheimer O, Cheung N-K, Gerald WL. The RET oncogene is a critical component of transcriptional programs associated with retinoic acid-induced differentiation in neuroblastoma. Mol Cancer Ther 2007;6:1300-1309.
67. Zage PE, Zeng L, Palla S, et al. A novel therapeutic combination for neuroblastoma: The VEGF/EGF/ RET inhibitor vandetanib with 13-cis-retinoic acid. Cancer 2010;116:2465-2475.
68. Grinshtein N, Datti A, Fujitani N, et al. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011;71:1385-1395.
69. Cole KA, Huggins J, Laquaglia M, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci USA 2011;108:3336-3341.
70. Balamuth NJ, Wood A, Wang Q, et al. Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. Cancer Res 2010;70:2749-2758.
71. Houghton PJ, Morton CL, Tucker C, et al. The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer 2007;49:928-940.
72. Cheung NK, Burch L, Kushner BH, et al. Monoclonal antibody 3F8 can effect durable remissions in neuroblastoma patients refractory to chemotherapy: A phase II trial. Prog Clin Biol Res 1991;366:395-400.
73. Cheung NK, Kushner BH, Yeh SJ, et al. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: A phase II study. Prog Clin Biol Res 1994;385:319-328.
74. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-4194.
75. Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992;35:199-204.
76. Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-193.
77. Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report from the Children's Cancer Group. Cancer 1997;80:317-333.
78. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-267.
79. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti disialoganglioside monoclonal antibody ch14.18 in patients with refractor neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-2180.
80. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I Study of Chimeric Human/Murine Anti-Ganglioside G(D2) Monoclonal Antibody (ch14.18) with Granulocyte-Macrophage Colony-Stimulating Factor in Children with Neuroblastoma Immediately After Hematopoietic Stem-Cell Translplantation: A Children's Cancer Group Study. J Clin Oncol 2000;18:4077-4085.
81. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: A report from the Children's Oncology Group. J Clin Oncol 2009;27:85-91.
82. Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-1759.
83. Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: A Children's Oncology Group Phase II Study. J Clin Oncol 2010;28:4969-4975.